MX367732B - Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma. - Google Patents

Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma.

Info

Publication number
MX367732B
MX367732B MX2016013114A MX2016013114A MX367732B MX 367732 B MX367732 B MX 367732B MX 2016013114 A MX2016013114 A MX 2016013114A MX 2016013114 A MX2016013114 A MX 2016013114A MX 367732 B MX367732 B MX 367732B
Authority
MX
Mexico
Prior art keywords
artemisinin
prevention
derivatives
treatment
seborrheic keratosis
Prior art date
Application number
MX2016013114A
Other languages
English (en)
Other versions
MX2016013114A (es
Inventor
Sift Carter Rosemarie
Original Assignee
Epipharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epipharm Ag filed Critical Epipharm Ag
Publication of MX2016013114A publication Critical patent/MX2016013114A/es
Publication of MX367732B publication Critical patent/MX367732B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con un método para tratar o prevenir la queratosis seborreica. El método comprende la aplicación local en un sujeto con necesidad de la misma artemisinina y/o uno o más compuestos relacionados estructuralmente. También se describen formulaciones tópicas que comprenden artemisinina y/o uno o más compuestos relacionados estructuralmente.
MX2016013114A 2014-04-28 2015-04-27 Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma. MX367732B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14166277 2014-04-28
PCT/EP2015/059104 WO2015165856A1 (en) 2014-04-28 2015-04-27 Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof

Publications (2)

Publication Number Publication Date
MX2016013114A MX2016013114A (es) 2017-02-14
MX367732B true MX367732B (es) 2019-09-04

Family

ID=50624467

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013114A MX367732B (es) 2014-04-28 2015-04-27 Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma.

Country Status (20)

Country Link
US (1) US9907782B2 (es)
EP (1) EP3137052B1 (es)
JP (1) JP6487459B2 (es)
KR (1) KR20160145818A (es)
CN (1) CN106456600B (es)
AU (1) AU2015252207B2 (es)
BR (1) BR112016024916A2 (es)
CA (1) CA2945646C (es)
DK (1) DK3137052T3 (es)
ES (1) ES2694623T3 (es)
HR (1) HRP20181981T1 (es)
IL (1) IL247909A0 (es)
MX (1) MX367732B (es)
PL (1) PL3137052T3 (es)
PT (1) PT3137052T (es)
RU (1) RU2702347C2 (es)
SG (1) SG11201607734PA (es)
SI (1) SI3137052T1 (es)
WO (1) WO2015165856A1 (es)
ZA (1) ZA201606837B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823789B (zh) * 2019-11-19 2024-05-10 强生外科视力公司 用于治疗眼睛的组合物和方法
WO2024112391A1 (en) * 2022-11-23 2024-05-30 Timber Pharmaceuticals, Inc. Compositions for local delivery of drug actives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2712861C2 (de) 1977-03-21 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 17-Acetoxy-6-chlor-15β-hydroxy-1α,2α-methylen-4,6-pregnadien-3,20-dion, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
US4916204A (en) * 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
JPH03170422A (ja) * 1989-11-22 1991-07-24 Dermatologic Res Corp 皮膚疾患の治療法
US7381427B2 (en) 2001-02-09 2008-06-03 Mickey Miller Seborrheic keratosis treatment
RU2006135552A (ru) * 2003-11-19 2008-04-20 Веста Лтд. (Il) Способы и составы для лечения заболеваний, связанных с helikobakter pyroli. с использованием соединений, содержащих эндопероксидный мостик
ATE511839T1 (de) * 2005-10-20 2011-06-15 Epipharm Gmbh Behandlung und prävention von gutartigen pigmentmalen (naevi) mit artemisinin und seinen derivaten
US8193376B2 (en) * 2007-01-01 2012-06-05 Bioderm Research Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals
KR100795515B1 (ko) * 2007-01-11 2008-01-16 바이오스펙트럼 주식회사 아테미시닌을 포함하는 피부 미백용 조성물
WO2009033494A1 (en) * 2007-09-10 2009-03-19 Dafra Pharma N.V. 1- or 2-substituted artemisinin derivatives for increasing the in vivo biological activity of biologically active compounds
WO2012080466A2 (en) * 2010-12-17 2012-06-21 Leo Pharma A/S Ingenols for treating seborrheic keratosis
KR20120085953A (ko) 2011-01-25 2012-08-02 원영두 피부미용제 및 그 제조방법
US9814659B2 (en) 2012-04-02 2017-11-14 Johnson & Johnson Consumer Inc. Methods of lightening the skin

Also Published As

Publication number Publication date
WO2015165856A1 (en) 2015-11-05
RU2016146373A3 (es) 2018-11-14
KR20160145818A (ko) 2016-12-20
DK3137052T3 (da) 2019-01-02
PL3137052T3 (pl) 2019-02-28
EP3137052A1 (en) 2017-03-08
SG11201607734PA (en) 2016-11-29
RU2016146373A (ru) 2018-05-28
HRP20181981T1 (hr) 2019-01-25
IL247909A0 (en) 2016-11-30
AU2015252207B2 (en) 2019-09-12
MX2016013114A (es) 2017-02-14
CN106456600B (zh) 2020-08-04
JP6487459B2 (ja) 2019-03-20
US20170035727A1 (en) 2017-02-09
PT3137052T (pt) 2018-11-30
JP2017516761A (ja) 2017-06-22
ES2694623T3 (es) 2018-12-26
RU2702347C2 (ru) 2019-10-08
ZA201606837B (en) 2022-05-25
EP3137052B1 (en) 2018-08-29
CN106456600A (zh) 2017-02-22
CA2945646C (en) 2020-12-15
AU2015252207A1 (en) 2016-10-06
CA2945646A1 (en) 2015-11-05
US9907782B2 (en) 2018-03-06
BR112016024916A2 (pt) 2017-08-15
NZ724402A (en) 2020-11-27
SI3137052T1 (sl) 2019-01-31

Similar Documents

Publication Publication Date Title
HK1251614A1 (zh) 用於惡性腫瘤的治療的方法
IL251215B (en) Cannabinoid preparation and method for treating pain
GB2541571A (en) Pharmaceutical compositions
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
SI3261726T1 (sl) Sestavek za zdravljenje aken
EP3242947A4 (en) Method for the treatment of malignancies
HK1258696A1 (zh) 治療或預防皮膚障礙的新型組合物和方法
HK1257234A1 (zh) 治療冠狀動脈粥樣硬化及其併發症的藥物及其用途
EP3352729A4 (en) METHODS AND COMPOSITIONS FOR TREATING SKIN
EP3316874A4 (en) TOPICAL AND INJECTABLE REYQUIMOD COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN DISEASES
EP3310377A4 (en) Method of treating crohn's disease
MY178971A (en) Triaminopyrimidine compounds useful for preventing or treating malaria
MX367732B (es) Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma.
IL268728A (en) Formulations of cannabinoids for the treatment of acne
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
EP3496738C0 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING HEART DAMAGE
EP3443090A4 (en) USE OF MIR-223-3P AS CANCER THERAPEUTIC AND METHOD FOR THE TREATMENT OF CANCER THEREWITH
EP3373947A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
PT3340975T (pt) Formulação para o tratamento de acne
IL272945A (en) Local preparations and methods of treatment
EP3386503A4 (en) METHOD AND FORMULATIONS FOR THE TREATMENT OF VASCULAR DISEASES
EP3080222A4 (en) Method for treating wood, wood product and use field of the invention
AU2016902517A0 (en) Formulation and method for the treatment of timber
PT3524255T (pt) Composição para o tratamento do acne
AU2015902286A0 (en) Method Of Treating Crohn's Disease

Legal Events

Date Code Title Description
FG Grant or registration